Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

被引：27
|
作者：
Fink, A. M. [1 ,2 ,15 ,16 ]
Bottcher, S. [3 ,15 ,16 ]
Ritgen, M. [3 ]
Fischer, K. [1 ,2 ]
Pflug, N. [1 ,2 ]
Eichhorst, B. [1 ,2 ]
Wendtner, C-M [1 ,2 ]
Winkler, D. [4 ]
Buhler, A. [4 ]
Zenz, T. [4 ,5 ,6 ,7 ]
Staib, P. [8 ]
Mayer, J. [9 ,10 ,11 ]
Hensel, M. [5 ,6 ,7 ]
Hopfinger, G. [12 ]
Wenger, M. [13 ]
Fingerle-Rowson, G. [1 ,2 ]
Dohner, H. [4 ]
Kneba, M. [3 ]
Stilgenbauer, S. [4 ]
Busch, R. [14 ]
Hallek, M. [1 ,2 ]
机构：
[1] Dept Internal Med 1, Cologne, Germany
[2] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany
[3] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany
[4] Klinikum Munchen Schwabing, Munich, Germany
[5] Univ Ulm, Dept Internal Med 3, Ulm, Germany
[6] Natl Ctr Tumor Dis NCT, Dept Translat Oncol, Heidelberg, Germany
[7] German Canc Res Ctr, Heidelberg, Germany
[8] Heidelberg Univ, Dept Med 5, Heidelberg, Germany
[9] St Antonius Hosp Eschweiler, Klin Hamatol & Onkol, Eschweiler, Germany
[10] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
[11] Masaryk Univ, CEITEC, Brno, Czech Republic
[12] Mannheimer Onkol Praxis, Mannheim, Germany
[13] Hanusch Hosp Vienna, Dept Med 3, Vienna, Austria
[14] Paracelsus Med Univ, Dept Med 3, Salzburg, Austria
[15] F Hoffmann Roche Ltd, Pharmaceut Div, Basel, Switzerland
[16] Tech Univ, Inst Med Stat & Epidemiol, Munich, Germany
来源：
LEUKEMIA | 2013年 / 27卷 / 09期
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; SURVIVAL; QUANTIFICATION; PROGRESSION;
D O I：
10.1038/leu.2013.190
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1949 / +
页数：5
相关论文
共 50 条
  • [31] Rituximab as first-line treatment of pemphigus
    Schmidt, Enno
    LANCET, 2017, 389 (10083): : 1956 - 1958
  • [32] Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL).
    O'Brien, S.
    Byrd, J. C.
    Kipps, T. J.
    Forero-Torres, A.
    Flinn, I. W.
    Wynne, D. I.
    Molina, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [33] Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL).
    Garcia-Manero, G
    O'Brien, S
    Cortes, J
    Giles, F
    Faderl, S
    Lerner, S
    Albitar, M
    Kantarjian, HM
    Keating, MJ
    BLOOD, 2000, 96 (11) : 757A - 757A
  • [34] Observational study in comorbid patients with CLL receiving first-line rituximab-bendamustine
    Spacek, Martin
    Doubek, Michael
    Obrtlikova, Petra
    Novak, Jan
    Trneny, Marek
    Hadrabova, Marketa
    Cmunt, Eduard
    Karban, Josef
    Molinsky, Jan
    Simkovic, Martin
    Mocikova, Heidi
    Smolej, Lukas
    Panovska, Anna
    Mohammadova, Lekaa
    LEUKEMIA & LYMPHOMA, 2017, 58 : 119 - 120
  • [35] A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma.
    Zinzani, PL
    BLOOD, 2001, 98 (11) : 842A - 842A
  • [36] Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL
    Wierda, W
    Faderl, S
    O'Brien, S
    Cortes, J
    Ferrajoli, A
    Giles, F
    Andreff, M
    Koller, C
    Kantarjian, H
    Keating, M
    BLOOD, 2004, 104 (11) : 101A - 101A
  • [37] Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas
    Fabbri, Alberto
    Cencini, Emanuele
    Rigacci, Luigi
    Bartalucci, Giulia
    Puccini, Benedetta
    Dottori, Roberto
    Gozzetti, Alessandro
    Bosi, Alberto
    Bocchia, Monica
    LEUKEMIA & LYMPHOMA, 2014, 55 (04) : 781 - 785
  • [38] Health Related Quality of Life (HRQOL) in Patients Receiving Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) or Fludarabine and Cyclophosphamide (FC) for First Line Therapy with Advanced Chronic Lymphocytic Leukemia (CLL)
    Eichhorst, Barbara F.
    Fischer, Kirsten
    Fink, Anna-Maria
    Fingerle-Rowson, Guenter
    Westermann, Anne
    Wendtner, Clemens-Martin
    Busch, Raymonde
    Hallek, Michael
    BLOOD, 2009, 114 (22) : 1336 - 1336
  • [39] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17p
    Jain, Nitin
    Thompson, Philip
    Burger, Jan
    Borthakur, Gautam
    Bose, Prithviraj
    Estrov, Zeev
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Garg, Naveen
    Wang, Xuemei
    Gandhi, Varsha
    Plunkett, William
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Lopez, Wanda
    Kantarjian, Hagop
    O'Brien, Susan
    Keating, Michael
    Wierda, William
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S13 - S14
  • [40] Ibrutinib and Venetoclax for First-Line Treatment of CLL
    Jain, Nitin
    Keating, Michael
    Thompson, Philip
    Ferrajoli, Alessandra
    Burger, Jan
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev
    Fowler, Nathan
    Kadia, Tapan
    Konopleva, Marina
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop
    Gandhi, Varsha
    Wierda, William
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22): : 2095 - 2103
12345